At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed advanced non-small cell lung cancer
- ✓Age 18-75 years
- ✓EGFR expression in tumor with immunohistochemical score ≥2+
- ✓CXCL13 factor positive rate ≥10%
- ✕Prior gene therapy or CAR-T treatment
- ✕Uncontrolled hypertension (>160/95), unstable coronary artery disease, uncontrolled arrhythmias, unstable angina, decompensated heart failure, or MI within 6 months
- ✕Severe liver and kidney dysfunction or consciousness disorders
- ✕Antitumor chemotherapy within 14 days before infusion (other than lymphocyte clearance)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer
In Brief
A Early Phase 1 clinical trial evaluating CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells for Non Small Cell Lung Cancer. Currently recruiting, targeting 11 participants across 1 site.
Detailed Summary
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
Study Details
Timeline
Interventions
The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.